← All trials
NCT00991939
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2010
- Primary completion
- Mar 1, 2013
- Completion date
- Mar 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 8
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- New England Research InstitutesLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- New England Research InstitutesOverall official - principal investigator
- Case Western Reserve UniversityOverall official - principal investigator
- Johns Hopkins UniversityOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- Tulane UniversityOverall official - principal investigator
- University of MarylandOverall official - principal investigator
- University of PittsburghOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- University of WisconsinOverall official - principal investigator
- University of OklahomaOverall official - principal investigator
- Cornell UniversityOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.